Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jul 22;68(1):e97.
doi: 10.1192/j.eurpsy.2025.10062.

A whole-brain voxel-based analysis of structural abnormalities in PTSD: An ENIGMA-PGC study

Cheryl R Z See  1 Shuqing Si  1 C Lexi Baird  2   3 Courtney C Haswell  2   3 Ahmed Hussain  2   3 Miranda Olff  4   5 Dick J Veltman  4 Jessie L Frijling  6 Mirjam van Zuiden  4   7 Saskia B J Koch  4   8 Laura Nawijn  4   9 Li Wang  10   11 Ye Zhu  10   11 Gen Li  10   12 Yuval Neria  13   14 Xi Zhu  13   14 Benjamin Suarez-Jimenez  15 Sigal Zilcha-Mano  16 Amit Lazarov  13   17 Jennifer S Stevens  18 Kerry Ressler  18   19   20 Negar Fani  18 Tanja Jovanovic  18   21 Sanne J H van Rooij  18 Milissa L Kaufman  20   22 Lauren A M Lebois  19   20 Isabelle M Rosso  20   23 Elizabeth A Olson  20   23 Justin T Baker  20   24 Scott R Sponheim  25   26 Seth G Disner  25   26 Nicholas D Davenport  25   26 Amit Etkin  27   28 Adi Maron-Katz  27 Murray B Stein  29 Martha E Shenton  30   31   32 Dan J Stein  33 Jonathan Ipser  33 Sheri-Michelle Koopowitz  33 Soraya Seedat  34   35 Stefan du Plessis  34   35 Leigh L van den Heuvel  34   35 Shmuel Lissek  36 Hannah Berg  36 Thomas Straube  37 David Hofman  37 Lee A Baugh  38   39   40 Gina L Forster  38   39   41 Raluca M Simons  39   42   43 Jeffrey S Simons  40   42 Vincent A Magnotta  44 Kelene A Fercho  38   39   40   45 Xin Wang  46 Andrew S Cotton  46 Erin N O'Leary  46 Hong Xie  47 Daniel W Grupe  48 Jack B Nitschke  49 Richard J Davidson  48   49   50 Christine L Larson  51 Terri A deRoon-Cassini  52   53 Carissa W Tomas  53   54 Jacklynn M Fitzgerald  55 Jennifer Urbano Blackford  56   57 Bunmi O Olatunji  58 Evan M Gordon  59 Geoffrey May  60   61   62   63 Steven M Nelson  64   65 Ruth Lanius  66 Jean Théberge  67 Maria Densmore  67 Richard W J Neufeld  67 Chadi G Abdallah  68   69 Christopher L Averill  68 Ilan Harpaz-Rotem  70   71 Ifat Levy  70   72 John H Krystal  69   70 Elbert Geuze  73   74 Remko van Lutterveld  73   74 Emily L Dennis  75   76   77   78 David F Tate  75   76 David X Cifu  79 William C Walker  79   80 Elisabeth A Wilde  75   76   81 Nic J A van der Wee  82   83 Robert R J M Vermeiren  82 Steven J A van der Werff  9   82   83 Katie McLaughlin  84 Kelly Sambrook  85 Matthew Peverill  86 Joaquim Radua  87 Lauren E Salminen  77 Neda Jahanshad  77 Sophia I Thomopoulos  77 Anthony James  88   89 Lucia Valmaggia  90   91   92 Paul M Thompson  77 Rajendra A Morey  2   3 Matthew J Kempton  1
Affiliations
Review

A whole-brain voxel-based analysis of structural abnormalities in PTSD: An ENIGMA-PGC study

Cheryl R Z See et al. Eur Psychiatry. .

Abstract

Background: Patients with posttraumatic stress disorder (PTSD) exhibit smaller regional brain volumes in commonly reported regions including the amygdala and hippocampus, regions associated with fear and memory processing. In the current study, we have conducted a voxel-based morphometry (VBM) meta-analysis using whole-brain statistical maps with neuroimaging data from the ENIGMA-PGC PTSD working group.

Methods: T1-weighted structural neuroimaging scans from 36 cohorts (PTSD n = 1309; controls n = 2198) were processed using a standardized VBM pipeline (ENIGMA-VBM tool). We meta-analyzed the resulting statistical maps for voxel-wise differences in gray matter (GM) and white matter (WM) volumes between PTSD patients and controls, performed subgroup analyses considering the trauma exposure of the controls, and examined associations between regional brain volumes and clinical variables including PTSD (CAPS-4/5, PCL-5) and depression severity (BDI-II, PHQ-9).

Results: PTSD patients exhibited smaller GM volumes across the frontal and temporal lobes, and cerebellum, with the most significant effect in the left cerebellum (Hedges' g = 0.22, pcorrected = .001), and smaller cerebellar WM volume (peak Hedges' g = 0.14, pcorrected = .008). We observed similar regional differences when comparing patients to trauma-exposed controls, suggesting these structural abnormalities may be specific to PTSD. Regression analyses revealed PTSD severity was negatively associated with GM volumes within the cerebellum (p corrected = .003), while depression severity was negatively associated with GM volumes within the cerebellum and superior frontal gyrus in patients (p corrected = .001).

Conclusions: PTSD patients exhibited widespread, regional differences in brain volumes where greater regional deficits appeared to reflect more severe symptoms. Our findings add to the growing literature implicating the cerebellum in PTSD psychopathology.

Keywords: PTSD; brain structure; gray matter volume; neuroimaging; trauma; voxel-based morphometry.

PubMed Disclaimer

Conflict of interest statement

N Jahanshad received partial research support from Biogen, Inc. (Boston, USA) for research unrelated to the content of this article. P Thompson received partial research support from Biogen, Inc. (Boston, USA) for research unrelated to the topic of this manuscript. R Davidson is the founder and president of, and serves on the board of directors for, the non-profit organization Healthy Minds Innovations, Inc. L Lebois reports unpaid membership on the Scientific Committee for the International Society for the Study of Trauma and Dissociation (ISSTD), grant support from the National Institute of Mental Health, K01 MH118467, and spousal IP payments from Vanderbilt University for technology licensed to Acadia Pharmaceuticals unrelated to the present work. ISSTD and NIMH were not involved in the analysis or preparation of the manuscript. C Abdullah has served as a consultant, speaker and/or on advisory boards for Douglas Pharmaceuticals, Freedom Biosciences, FSV7, Lundbeck, Psilocybin Labs, Genentech, Janssen and Aptinyx; served as editor of Chronic Stress for Sage Publications, Inc; and filed a patent for using mTOR inhibitors to augment the effects of antidepressants (filed on August 20, 2018). J Krystal is a consultant for AbbVie, Inc., Amgen, Astellas Pharma Global Development, Inc., AstraZeneca Pharmaceuticals, Biomedisyn Corporation, Bristol-Myers Squibb, Eli Lilly and Company, Euthymics Bioscience, Inc., Neurovance, Inc., FORUM Pharmaceuticals, Janssen Research & Development, Lundbeck Research USA, Novartis Pharma AG, Otsuka America Pharmaceutical, Inc., Sage Therapeutics, Inc., Sunovion Pharmaceuticals, Inc., and Takeda Industries; is on the Scientific Advisory Board for Lohocla Research Corporation, Mnemosyne Pharmaceuticals, Inc., Naurex, Inc., and Pfizer; is a stockholder in Biohaven Pharmaceuticals; holds stock options in Mnemosyne Pharmaceuticals, Inc.; holds patents for Dopamine and Noradrenergic Reuptake Inhibitors in Treatment of Schizophrenia, US Patent No. 5,447,948 (issued September 5, 1995), and Glutamate Modulating Agents in the Treatment of Mental Disorders, U.S. Patent No. 8,778,979 (issued July 15, 2014); and filed a patent for Intranasal Administration of Ketamine to Treat Depression. U.S. Application No. 14/197,767 (filed on March 5, 2014); US application or Patent Cooperation Treaty international application No. 14/306,382 (filed on June 17, 2014). Filed a patent for using mTOR inhibitors to augment the effects of antidepressants (filed on August 20, 2018). S Nelson consults for Turing Medical, which commercializes FIRMM. This interest has been reviewed and managed by the University of Minnesota in accordance with its Conflict of Interest policies. E Olson is employed by the nonprofit organization Crisis Text Line, for work unrelated to the content of this manuscript. All other authors report no potential competing interests or disclosures.

Figures

Figure 1.
Figure 1.
Patients with PTSD exhibited lower regional gray matter volume compared to controls throughout the brain as seen in the orange highlighted regions in the figure, with a peak effect in the left cerebellum [−4,−72,-10] (see also Supplementary Table S6).
Figure 2.
Figure 2.
The blue highlighted regions represent smaller gray matter volumes associated with: (A) higher PTSD severity scores, with the peak effect in the right cerebellum [4,−48,−58]; and (B) higher depression severity scores, with the peak effect in the right superior frontal gyrus [14, 66, 6] (see also Supplementary Tables S12 and S13).

Similar articles

References

    1. Benjet C, Bromet E, Karam EG, Kessler RC, McLaughlin KA, Ruscio AM, et al. The epidemiology of traumatic event exposure worldwide: Results from the world mental health survey consortium. Psychol Med. 2016;46(2):327–43. 10.1017/S0033291715001981. - DOI - PMC - PubMed
    1. Kilpatrick DG, Resnick HS, Milanak ME, Miller MW, Keyes KM, Friedman MJ. National estimates of exposure to traumatic events and PTSD prevalence using DSM-IV and DSM-5 criteria. J Trauma Stress. 2013;26(5):537–47. 10.1002/jts.21848. - DOI - PMC - PubMed
    1. Association AP. Diagnostic and statistical manual of mental disorders. 5th ed. American Psychiatric Association; 2013.
    1. Bromis K, Calem M, Reinders A, Williams SCR, Kempton MJ. Meta-analysis of 89 structural MRI studies in posttraumatic stress disorder and comparison with major depressive disorder. Am J Psychiatry. 2018;175(10):989–98. 10.1176/appi.ajp.2018.17111199. - DOI - PMC - PubMed
    1. Siehl S, Zohair R, Guldner S, Nees F. Gray matter differences in adults and children with posttraumatic stress disorder: A systematic review and meta-analysis of 113 studies and 11 meta-analyses. J Affect Disord. 2023;333:489–516. 10.1016/j.jad.2023.04.028. - DOI - PubMed

Grants and funding